People
Biotech CFOs, optimistic about economic recovery as COVID-19 vaccines role out, are busy digitally transforming their companies for a post-COVID way of working, according to the 2021 BDO Life Sciences CFO Outlook Survey, released January 11.
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
With the new year comes a changing of the guard at Pfizer. After two years of helming the company’s pharma operations, Chief Medical Officer Mace Rothenberg announced his departure from Pfizer on social media.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
Former U.S. Rep. Chris Collins spent less than a year in federal prison for pleading guilty to violating felony insider trading laws when he sat on the board of directors of Innate Therapeutics. On Tuesday, Collins received a pardon from President Donald Trump.
PRESS RELEASES
